← Back to screener

Amylyx Pharmaceuticals, Inc. AMLX

Rank #2348 · Nasdaq · $3.2B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
22.9
P/E
-10.6
P/B
7.40
ROE
-69.6%
Op. Margin
-360.2%
Debt Ratio
7%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -10.6x, P/B 7.40x. Ranks in the top 79% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -69.6%. Ranks in the top 93% of the universe.

Safety ★★★★★
Excellent

Debt ratio 7%. Ranks in the top 9% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 77.1% year over year. Ranks in the top 99% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2022$0.0B$-0.1B$-0.1B$-0.1B-29013.3-26
2023$0.0B$-0.1B$-0.1B$-0.1B-29013.3-76
2024$0.4B$0.0B$0.0B$0.3B10.225
2025$0.1B$-0.3B$-0.3B$0.4B-360.27

← See the full screener